A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Epistemonikos ID: 87ab267063fb57ef27629f13636aff69096586c0
First added on: May 22, 2024